Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Esophageal Neoplasms 9Melanoma 6Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Transitional Cell 2Unresectable Biliary Tract Cancer 1Thymus Neoplasms 1Thymoma 1Thymic epithelial tumor 1Small Cell Lung Cancer Extensive Stage 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pathologic Complete Response 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Neoplasms 1Muscle-Invasive Bladder Carcinoma 1

Interventions

Injections 12pembrolizumab 7toripalimab 5tislelizumab 5Oxaliplatin 3Gemcitabine 3Cisplatin 3Carboplatin 3trastuzumab deruxtecan 2spartalizumab 2lenvatinib 2atezolizumab 2Paclitaxel 2Nivolumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2zimberelimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1fludarabine phosphate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumor × Immunotherapy × Clear all
NCT06173219 2025-02-27

Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.

China-Japan Friendship Hospital

Phase 1/2 Recruiting
38 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡